How many drugs treat Post-Op Ocular Inflammation?

Drug Landscape tracks 10 marketed treatments for Post-Op Ocular Inflammation (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/post-op-ocular-inflammation.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Post-Op Ocular Inflammation — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-Op Ocular Inflammation (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Post-Op Ocular Inflammation, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Durezol	DIFLUPREDNATE	Novartis	difluprednate	Glucocorticoid receptor	2008-01-01
Nevanac	NEPAFENAC	Harrow Health	Nonsteroidal Anti-inflammatory Drug [EPC]	Prostaglandin G/H synthase 2	2005-01-01
Xibrom	BROMFENAC	Bausch Health	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	2005-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1998-01-01
Arthrotec	Diclofenac Sodium	Pfizer	diclofenac	Acid-sensing ion channel 3	1988-01-01
Voltaren	DICLOFENAC	Hisamitsu Pharmaceutical Co., Inc	Nonsteroidal Anti-inflammatory Drug	Prostaglandin G/H synthase 2	1988-01-01
Flarex	FLUOROMETHOLONE ACETATE	Harrow Health	Corticosteroid	Glucocorticoid receptor	1986-01-01
Fml	FLUOROMETHOLONE	AbbVie	Corticosteroid	Glucocorticoid receptor	1972-01-01
Medrifar	MEDRYSONE	AbbVie	Corticosteroid	Glucocorticoid receptor	1969-01-01
Tham	trometamol	Pfizer	trometamol		1965-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Post-Op Ocular Inflammation
Pfizer · 2 drugs in Post-Op Ocular Inflammation
Harrow Health · 2 drugs in Post-Op Ocular Inflammation
AbbVie · 2 drugs in Post-Op Ocular Inflammation
Bausch Health · 2 drugs in Post-Op Ocular Inflammation
Hannover Medical School · 1 drug in Post-Op Ocular Inflammation
Harrow Eye · 1 drug in Post-Op Ocular Inflammation
Hisamitsu Pharmaceutical Co., Inc · 1 drug in Post-Op Ocular Inflammation
Novartis · 1 drug in Post-Op Ocular Inflammation
Santa Casa de Misericordia de Santos · 1 drug in Post-Op Ocular Inflammation
Tufts Medical Center · 1 drug in Post-Op Ocular Inflammation
University of Trieste · 1 drug in Post-Op Ocular Inflammation

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Post-Op Ocular Inflammation:

Cite this brief

Drug Landscape (2026). Post-Op Ocular Inflammation — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/post-op-ocular-inflammation. Accessed 2026-06-10.

Post-Op Ocular Inflammation full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing